MicroRNA-378 Enhances Radiation Response in Ectopic and Orthotopic Implantation Models of Glioblastoma
Overview
Authors
Affiliations
Glioblastoma multiforme (GBM) is the most common and highly malignant primary brain tumor, which is virtually incurable due to its therapeutic resistance to radiation and chemotherapy. To develop novel therapeutic approaches for treatment of GBM, we examined the role of miR-378 on tumor growth, angiogenesis, and radiation response in ectopic and orthotopic U87 glioblastoma models. Cell and tumor growth rates, in vitro and in vivo radiation sensitivities, and tumor vascular density were evaluated in U87-GFP and U87-miR-378 tumor lines. Ectopic tumor response to radiation was evaluated under normal blood flow and clamp hypoxic conditions. Results show that in vitro, miR-378 expression moderately increased cell growth rate and plating efficiency, but did not alter radiation sensitivity. U87-miR-378 tumors exhibited a higher transplantation take rate than U87-GFP tumors. In vivo, under oxygenated condition, subcutaneous U87-miR-378 tumors receiving 25 Gy showed a tendency for longer tumor growth delay (TGD) than control U87-GFP tumors. In contrast, under hypoxic condition, U87-miR-378 xenografts exhibited substantially shorter TGD than U87-GFP tumors, indicating that under normal blood flow conditions, U87-miR-378 tumors were substantially more oxygenated than U87-GFP tumors. Intracranial multi-photon laser-scanning microscopy demonstrated increased vascular density of U87-miR-378 versus control U87-GFP tumors. Finally, miR-378 increased TGD following 12 Gy irradiation in U87 intracranial xenografts, and significantly prolonged survival of U87-miR-378 tumor-bearing mice (P = 0.04). In conclusion, higher miR-378 expression in U87-miR-378 cells promotes tumor growth, angiogenesis, radiation-induced TGD, and prolongs survival of orthotopic tumor-bearing hosts. Regulation of VEGFR2 by miR-378 significantly increased vascular density and oxygenation in U87 xenografts.
Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance in Cancer Cells.
Jalali-Zefrei F, Mousavi S, Delpasand K, Shourmij M, Farzipour S Curr Gene Ther. 2024; 25(2):113-135.
PMID: 38676526 DOI: 10.2174/0115665232301727240422092311.
miRNA-378 Is Downregulated by XBP1 and Inhibits Growth and Migration of Luminal Breast Cancer Cells.
Arabkari V, Barua D, Hossain M, Webber M, Smith T, Gupta A Int J Mol Sci. 2024; 25(1).
PMID: 38203358 PMC: 10778669. DOI: 10.3390/ijms25010186.
Advances in Diagnostic Tools and Therapeutic Approaches for Gliomas: A Comprehensive Review.
Thenuwara G, Curtin J, Tian F Sensors (Basel). 2023; 23(24).
PMID: 38139688 PMC: 10747598. DOI: 10.3390/s23249842.
Schulz J, Hartz A, Bauer B Pharmacol Rev. 2023; 75(5):815-853.
PMID: 36973040 PMC: 10441638. DOI: 10.1124/pharmrev.120.000025.
Depicting the Implication of miR-378a in Cancers.
Qin Y, Liang R, Lu P, Lai L, Zhu X Technol Cancer Res Treat. 2022; 21:15330338221134385.
PMID: 36285472 PMC: 9608056. DOI: 10.1177/15330338221134385.